Regeneron announced Friday that the company won Food and Drug Administration ... in the lungs and widens the airways.

This makes the new indication for Dupixent very important for Sanofi as it searches for a blockbuster to transform its fortunes. The FDA is set to make a decision on Dupixent’s new indication on ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

It's waiting on the results of trials in additional indications – chronic-inducible urticaria and food allergies – before planning its next steps. Dupixent is already approved to treat a range ...